|Melanoma sentinel node biopsy and prediction models for relapse and overall survival.|
|Jump to Full Text|
|PMID: 20859289 Owner: NLM Status: MEDLINE|
|BACKGROUND: To optimise predictive models for sentinal node biopsy (SNB) positivity, relapse and survival, using clinico-pathological characteristics and osteopontin gene expression in primary melanomas.
METHODS: A comparison of the clinico-pathological characteristics of SNB positive and negative cases was carried out in 561 melanoma patients. In 199 patients, gene expression in formalin-fixed primary tumours was studied using Illumina's DASL assay. A cross validation approach was used to test prognostic predictive models and receiver operating characteristic curves were produced.
RESULTS: Independent predictors of SNB positivity were Breslow thickness, mitotic count and tumour site. Osteopontin expression best predicted SNB positivity (P=2.4 × 10⁻⁷), remaining significant in multivariable analysis. Osteopontin expression, combined with thickness, mitotic count and site, gave the best area under the curve (AUC) to predict SNB positivity (72.6%). Independent predictors of relapse-free survival were SNB status, thickness, site, ulceration and vessel invasion, whereas only SNB status and thickness predicted overall survival. Using clinico-pathological features (thickness, mitotic count, ulceration, vessel invasion, site, age and sex) gave a better AUC to predict relapse (71.0%) and survival (70.0%) than SNB status alone (57.0, 55.0%). In patients with gene expression data, the SNB status combined with the clinico-pathological features produced the best prediction of relapse (72.7%) and survival (69.0%), which was not increased further with osteopontin expression (72.7, 68.0%).
CONCLUSION: Use of these models should be tested in other data sets in order to improve predictive and prognostic data for patients.
|A Mitra; C Conway; C Walker; M Cook; B Powell; S Lobo; M Chan; M Kissin; G Layer; J Smallwood; C Ottensmeier; P Stanley; H Peach; H Chong; F Elliott; M M Iles; J Nsengimana; J H Barrett; D T Bishop; J A Newton-Bishop|
Related Documents :
|9731839 - Expression of gamma-glutamyl transpeptidase in stage iii and iv ovarian surface epithel...
10371339 - Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to ...
17127229 - Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic...
19381079 - Perineural invasion after preoperative chemotherapy predicts poor survival in patients ...
17137709 - Placenta growth factor not vascular endothelial growth factor a or c can predict the ea...
18847499 - Prognostic significance of vegf expression in patients with bulky cervical carcinoma un...
12067139 - Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial emboliza...
7492009 - A selective therapeutic approach to gastric cancer in a large public hospital.
22076799 - Improvement in survival during the past 4 decades among patients with anterior skull ba...
|Type: Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies Date: 2010-09-21|
|Title: British journal of cancer Volume: 103 ISSN: 1532-1827 ISO Abbreviation: Br. J. Cancer Publication Date: 2010 Oct|
|Created Date: 2010-10-12 Completed Date: 2010-11-04 Revised Date: 2014-03-17|
Medline Journal Info:
|Nlm Unique ID: 0370635 Medline TA: Br J Cancer Country: England|
|Languages: eng Pagination: 1229-36 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Aged, 80 and over
Gene Expression Regulation, Neoplastic
Melanoma / diagnosis*, genetics, mortality*, pathology
Randomized Controlled Trials as Topic
Sentinel Lymph Node Biopsy*
Skin Neoplasms / diagnosis*, genetics, mortality*, pathology
Tumor Markers, Biological / analysis, genetics
|10589//Cancer Research UK; C588/A4994//Cancer Research UK; C8216/A6129//Cancer Research UK; C8216/A8168//Cancer Research UK|
|0/Tumor Markers, Biological|
Journal ID (nlm-ta): Br J Cancer
Publisher: Nature Publishing Group
Copyright © 2010 Cancer Research UK
Received Day: 12 Month: 04 Year: 2010
Revision Received Day: 07 Month: 07 Year: 2010
Accepted Day: 16 Month: 07 Year: 2010
Print publication date: Day: 12 Month: 10 Year: 2010
Electronic publication date: Day: 21 Month: 09 Year: 2010
Volume: 103 Issue: 8
First Page: 1229 Last Page: 1236
Publisher Item Identifier: 6605849
PubMed Id: 20859289
|Melanoma sentinel node biopsy and prediction models for relapse and overall survival Alternate Title:SNB predictive models|
|M M Iles1|
|J H Barrett1|
|D T Bishop1|
|J A Newton-Bishop1|
1Section of Epidemiology and Biostatistics, Leeds Institute of Molecular Medicine, St James's University Hospital, Beckett Street, Leeds LS97TF, UK
2Royal Surrey County Hospitals NHS Trust, Surrey, UK
3St Georges's Hospital Melanoma Unit, Blackshaw Road, Tooting, London, UK
4Southampton University Hospitals NHS Trust, Tremona Road, Southampton, UK
5Hull and East Yorkshire Hospitals NHS Trust, Castle Hill Road, Hull, UK
6Leeds Teaching Hospitals Trust, Beckett Street, Leeds, UK
Several clinico-pathological characteristics of primary melanoma have been identified as independent prognostic factors for relapse and overall survival (OS), including age, sex, tumour site, Breslow thickness, ulceration, mitotic count, vessel invasion, regression and the presence of tumour-infiltrating lymphocytes (TILs) (Johnson et al, 1985; Clark et al, 1989; Cochran et al, 2000; Balch et al, 2001). Although as yet no OS benefit has been demonstrated from sentinal node biopsy (SNB) (Morton et al, 2006), the SNB status has been determined to be the single most important prognostic factor for melanoma (Gershenwald et al, 1999; Ferrone et al, 2002; Gutzmer et al, 2008) and is used in the American Joint Committee on Cancer (AJCC) staging system for cutaneous melanoma.
Breslow thickness is usually used to identify patients for SNB, but it has been shown to have poor sensitivity and specificity in predicting positivity (Sondak et al, 2004). Several groups have attempted to identify predictors of SNB positivity using clinical and histological characteristics of the primary melanoma, but so far only thickness has been consistently identified (Sondak et al, 2004), and it therefore remains the most commonly used criterion in selecting patients for SNB. If SNB is limited to melanoma patients with a tumour thickness ⩾1 mm, then micrometastases (SNB positivity) are detected in around 24% (Lens et al, 2002). The purpose of this study was to identify characteristics of primary melanoma, which better predict SNB positivity; to identify predictors of relapse-free survival (RFS) and OS and also to identify genetic prognostic biomarkers allowing further insight into the biological pathways important in melanoma progression.
We have used Illumina's DASL (cDNA-mediated annealing, selection, extension and ligation) assay (Illumina, Service XS, Leiden, Netherlands) to investigate prognostic biomarkers in formalin-fixed paraffin-embedded (FFPE) primary melanomas. This is a novel assay designed specifically to generate reproducible RNA profiles from FFPE tissue, in which the extracted RNA is often significantly degraded: partially degraded RNA has breaks throughout the RNA transcript making it difficult to generate high-quality full-length cDNA. The DASL assay uses random priming during cDNA synthesis, which means it does not depend on an intact poly-A tail, and in addition it only requires the probes to span about 50 bases and is therefore adapted to degraded RNA (Illumina, 2005a, 2005b). Gene expression studies in FFPE melanomas have been relatively few in number, and most studies have predominantly used immunohistochemical staining and polymerase chain reaction techniques, allowing only a few genes to be analysed at a time. More recently, Winnepenninckx et al (2006) identified a 254-gene signature predictive of survival in 83 cryopreserved primary tumours, and Kauffmann et al (2008) identified increased expression of DNA repair genes in metastatic melanoma tumours from 60 tumour samples. Two small previous studies using cryopreserved tumours also showed a correlation between osteopontin expression and progression in melanoma (Zhou et al, 2005; Jaeger et al, 2007). We have recently reported the successful use of the DASL assay in melanoma primaries (Conway et al, 2009).
Patients with melanomas of Breslow thickness ⩾0.75 mm having undergone SNB were recruited to a multicentre retrospective study. A cutoff of 0.75 mm rather than 1 mm was chosen, as we were aware that participating centres had historically carried out SNBs for <1 mm melanomas based on other histological criteria, such as vertical growth phase, Clark's level IV/V and regression. The study was approved both by the UK national ethics committees (MREC: multicentre research ethics committee and PIAG: patient information advisory group), which determined that patients still under follow-up at the cancer centre should be consented to use of their tissues. Five centres from the United Kingdom (St George's Hospital, London; Royal Surrey County Hospital, Guildford; Southampton General Hospital, Southampton; Castle Hill Hospital, Hull and St James's University Hospital, Leeds) identified all patients having had SNB in their departments from November 1994 until 2006. The first 400 patients to have a positive SNB were selected. As more patients undergoing SNB have a negative than a positive SNB result, a subset of SNB-negative patients were randomly selected, frequency matched by year of SNB and by the centre at which the SNB was performed. Patients were excluded if they had previous cancers other than non-melanoma skin cancer or cervical carcinoma in situ or if they had multiple melanoma primaries. Sample size calculations based on 250 patients in each group showed that the minimum detectable odds ratio (OR) for predicting SNB positivity would be 2.2, with a power of 80% and a significance level of 0.001 assuming a risk factor prevalence of 0.4 and based on 50 independent factors being analysed to produce a study-wide significance level of 0.05.
Clinico-pathological characteristics were extracted from clinical files: age, sex, site of primary tumour, clinical maximal diameter of tumour as measured macroscopically by the pathologist, Breslow thickness, Clark's level, histological subtype, mitotic count (mm−2), presence or absence of ulceration, regression, vessel invasion, perineural invasion, TILs and microsatellites in either the primary or wider excision. In a proportion of the cases, factors such as ulceration (21.6%), regression (19.6%), vessel invasion (30.3%), perineural invasion (59.9%) and microsatellites (57.3%) were not mentioned in histology reports and were assumed to be absent for purpose of analysis. A sensitivity analysis on the completed data set for these five factors showed quantitatively similar results. Follow-up data were similarly extracted from clinical files. The date of first relapse in any site (local, in-transit, regional or distal) was used to calculate RFS. Relapse-free survival and OS were calculated from the date of primary diagnosis to time point of the recurrence or death or last follow-up.
Two hundred patients with a positive SNB who were first to undergo the procedure were identified, and the stored FFPE primaries were sought. We then randomly selected 100 of the patients with a negative SNB, from groups matched by SNB year, centre and sex, and their primary tumour blocks were also traced. A tissue microarray needle was then used to sample the advancing edge of the tumour (containing the lowest admixture of inflammatory or stromal cells) horizontally producing a 0.8 mm core of tumour as described previously (Conway et al, 2009). RNA was extracted from these tumour cores using the protocol in the High Pure Paraffin RNA Kit (Roche Diagnostics Ltd, Burges Hill, UK) and supplied to a service provider for gene expression studies using the Illumina DASL Cancer Panel, which targets 502 cancer genes with unique probes in three different locations per gene (Illumina, 2005b). Use of this technique by our group and the quality control measures used are described elsewhere (Conway et al, 2009).
Predictors of SNB positivity, RFS and OS were identified by univariable and multivariable analyses using STATA version 9 (StataCorp 2007, College Station, TX, USA). Breslow thickness was examined as a categorical variable using the same classification as the AJCC staging system (Balch et al, 2003). Mitotic count was classified as absent, low (1–6 mm−2) or high (>6 mm−2) (Elder and Murphy, 1991). Tumour sites were grouped into four, as arms, head and neck, legs or trunk. Age and clinical diameter of the primary melanoma were analysed as continuous variables. For associations with SNB positivity, continuous variables were analysed using t-tests and categorical variables using χ2 contingency table tests. Simple logistic regression was used to obtain ORs and 95% confidence intervals (CIs). The determinants of RFS and OS were identified using Cox's proportional hazards model to give hazard ratios (HR) and 95% CI. Multiple forward and backward stepwise logistic regression analyses were then performed to identify independent predictors of SNB positivity, RFS and OS. A significance level of P<0.05 was used.
The gene expression data were normalised within BeadStudio Gene Expression Module v3.4 (Illumina, San Diego, CA, USA) before exporting to STATA version 9 for statistical analyses. Fluorescence intensities from Cy3 and Cy5 dyes were averaged for each probe and the expression level of each gene was computed as an average of the intensities from three probes. Background correction and cubic B-spline smoothing methods (Workman et al, 2002) were used and sample scaling was applied to remove the variation between plates. Samples that failed to express over 250 genes were classified as failed and excluded from further analysis. Mean gene expression was calculated for the sample replicates. Expression of each gene was transformed to a log2 scale so that an increase of one unit corresponds to a doubling of expression levels; comparison between samples categorised by histological variables was carried out using two-sample t-tests and regression. Survival analysis was performed using a separate Cox's proportional hazards model for each gene. Using a Bonferroni correction for multiple testing, the significance level was set at 0.0001 for these univariable analyses.
A cross-validation approach implemented in R (version 2.8.0.) (Team, 2010) was used to estimate the predictive ability of the different prognostic models. Ten percent of the data were excluded, the model fitted to the remaining 90% and the predictive ability of this model on the excluded 10% was evaluated. This process was repeated 1000 times, excluding a random 10% each time, and the results were averaged.
A combined total of 2044 sentinel node biopsies were carried out in the five participating centres, and 439 patients had a positive result (21.5%). From initial lists provided by the five centres, previously recorded data on Breslow thickness was available in 1570 patients (70%). Overall, 320 patients (20%) had an SNB carried out for a melanoma <1 mm, and from this group, 24 patients (7.5%) had a positive SNB.
After identification of SNB positive and negative patients as described above, a total of 701 patients' case notes were reviewed, of whom 608 patients met the inclusion criteria. Of these 608 patients, 2 refused participation in the study and 45 did not reply to the invitation to participate, leaving 561 patients' data sets available for analysis. The majority of these patients (73%) were recruited from St George's Hospital, Melanoma Unit London, where SNB had been carried out for the longest period. In total, 218 FFPE primary tumours were collected. Of these, 199 blocks were selected for sampling. Reasons for not sampling a block included too little residual tumour after sectioning for clinical purposes or other research projects, tumour cells being mixed with large numbers of normal stromal or inflammatory cells, or because the wrong blocks were sent. Only two (0.9%) of the extracted samples were classified as failed samples. One of these failed samples was a technical replicate, which left 198 tumour samples for analysis. The mean age of the blocks was 6.26 years (range 2.23–15.16 years). Increasing age of block was associated with decreased gene detection (Spearman's correlation −0.24, P=0.0002) (Conway et al, 2009).
Table 1 shows the clinico-pathological characteristics of the patients in the total study group and in the tumour subset. Owing to the selection process, sentinel lymph nodes were positive for tumours in 286 of 561 patients (51.0%) in the total study group and in 131 of 198 patients whose FFPE tumours were sampled (66.2%) (the tumour subset). In our study group, there were 68 patients with a Breslow thickness between 0.75 and 1 mm (14 had a positive SNB, 20.6%). The median follow-up time for the total study group was 29.5 and 38.4 months for the tumour subset.
Table 2 shows the results of univariable unadjusted χ2 analysis and age/sex-adjusted logistic regression analysis of clinico-pathological factors associated with SNB positivity. In single variable analyses, the clinico-pathological factors associated with an increased risk of SNB positivity were increasing Breslow thickness (overall χ2, P=<0.0001), Clark's level (overall χ2, P=0.001), higher mitotic count (overall χ2, P<0.0001), presence of ulceration (P=<0.0001), presence of vessel invasion (P=0.02), presence of microsatellites (P=0.007), tumour site (overall χ2, P=0.04) and histological subtype (overall χ2, P=0.005). Patients with tumours situated on the leg or trunk showed a higher risk of SNB positivity than those with tumours on the arm (P=0.02, 0.007, respectively). Patients with nodular melanomas showed a higher risk of SNB positivity compared with patients with superficial spreading melanomas (P=0.02). Factors associated with a decreased risk of SNB positivity were the presence of more TILs (P=0.04) and the presence of regression (P=0.05). Factors not found to be significantly associated with SNB positivity were age, sex, perineural invasion and clinical diameter of the primary melanoma.
Clark's level and histological subtype were mentioned in histology reports less frequently than other variables, indicating higher amounts of missing data. These variables were therefore not included in the multivariable analyses. However, both Clark's level and histological subtype showed a strong correlation with Breslow thickness (Spearman's correlation 0.4, P<0.00001), and in the subset of individuals without missing data they were not independently significantly associated with SNB positivity once adjustment was made for Breslow thickness alone. The remaining significant prognostic factors adjusting for age and sex were entered into a stepwise logistic regression model, which revealed that the independent predictors of SNB positivity were thickness, mitotic count and tumour site (Table 3). The results were the same using either forwards or backwards selection.
The gene whose expression was most predictive of SNB positivity in univariable analysis in this study was osteopontin (SPP1), (OR 2.7 for each doubling of expression levels, 95% CI (1.8–4.1), P=2.4 × 10−7). This was the only gene on the DASL cancer panel to be significantly associated with SNB positivity following Bonferroni correction. This association persisted in multivariable analysis adjusting for age, sex and tumour site (OR 3.1, 95% CI (2.0–4.8), P=<0.0001), and when adjusted additionally for thickness, mitotic count, presence of ulceration and vessel invasion (OR 2.3, 95% CI (1.4–3.8), P=0.001). The fold change of expression signal was 1.6 between negative and positive SNB patients in unadjusted analysis. Osteopontin was also the gene most associated with increasing tumour thickness (P=3.15 × 10−11, Spearman's correlation 0.42). It also showed significant association with increasing mitotic count (P=0.0009, Spearman's correlation 0.24).
Using the total study group, we found that SNB positivity was best predicted by a model including thickness, mitotic count, tumour site, age and sex, giving an area under the curve (AUC) of 68.0%, compared with using a model using thickness alone, which gave an AUC of 58.0%. Figure 1 shows the receiver operating characteristic (ROC) curves for prediction of SNB positivity if osteopontin is included in the prognostic models using patients from the tumour subset. Osteopontin expression gave a better AUC (65.7%) than Breslow thickness alone (60.9%) in the tumour subset. Use of clinico-pathological features (thickness, mitotic count, site, age and sex) increased the AUC to 68.6%. However the best AUC of 72.6% was seen using a combination of osteopontin expression and the clinico-pathological variables together.
Univariable clinical predictors of poor RFS included increasing age (HR 1.01 for each year, 95% CI (1.00–1.03), P=0.01), male sex (HR 1.6, 95% CI (1.1–2.4), P=0.007), increasing clinical diameter of the tumour (HR 1.03, 95% CI (1.01–1.05), P=<0.0001) and tumour site (P=0.007). Patients with tumours on the head and neck (HR 3.1, 95% CI (1.5–6.5), P=0.003) and tumours on the trunk (HR 2.0, 95% CI (1.1–3.5), P=0.02) were more likely to relapse than patients with tumours on the arm. Histological predictors of poorer RFS by univariable analysis included SNB positivity (HR 4.6, 95% CI (2.8–7.6), P=<0.0001), increasing Breslow thickness (P<0.0001), increasing mitotic count (P=<0.0001), increasing Clark's level (P=<0.0001), presence of ulceration (HR 2.7, 95% CI (1.9–3.9), P=<0.0001), presence of vessel invasion (HR 4.0, 95% CI (2.2–7.1), P=<0.0001) and the presence of microsatellites (HR 2.8, 95% CI (1.5–5.2), P=0.001). Improved RFS was seen with a brisk TILs reaction (HR 0.3, 95% CI (0.1–0.6), P=0.001).
Univariable clinical predictors of poor OS were male sex (HR 1.8, 95% CI (1.1–2.8), P=0.02), increasing tumour diameter macroscopically (HR 1.04, 95% CI (1.02–1.06), P=0.001) and tumour site (P=0.01). Patients with tumours on the trunk were significantly less likely to survive than patients with tumours on the arm (HR 2.8, 95% CI (1.3–5.9), P=0.009). Histological predictors of poorer OS by univariable analysis included SNB positivity (HR 5.9, 95% CI (2.8–12.3), P=<0.0001), increasing Breslow thickness (P<0.0001), increasing mitotic count (P=<0.0001), increasing Clark's level (P=<0.0001), presence of ulceration (HR 2.4, 95% CI (1.5–3.8), P=<0.0001), presence of vessel invasion (HR 2.9, 95% CI (1.3–6.4), P=0.01) and presence of microsatellites (HR 3.3 95% CI (1.6–7.0), P=0.001). Improved OS was seen with a brisk TILs reaction (HR 0.3, 95% CI (0.1–0.8), P=0.02).
Clinical diameter of the lesion was not included in the multivariable analysis of RFS and OS due to concerns about the accuracy of measurement. The clinical diameter of the lesion however showed strong correlation to Breslow thickness (Spearman's correlation 0.3, P<0.00001) and did remain significant after adjusting for Breslow thickness alone as a predictor of reduced RFS and OS. Clark's level was also once again not included in multivariable analysis of RFS and OS due to missing data, but was not significant as a predictor of reduced RFS or OS once adjustment for Breslow thickness was made. Table 3 shows multivariate stepwise logistic regression for RFS and OS showing that the SNB status was the most significant single predictor of both RFS and OS. Other independent predictors of RFS were thickness, ulceration and vessel invasion. Breslow thickness was also an independent predictor of OS.
Increased osteopontin expression was also associated with reduced RFS (HR 1.6 for each doubling in expression levels, 95% CI (1.1–2.3), P=0.006) in unadjusted analyses, with a fold change of 1.32 between relapsers and non-relapsers. Osteopontin expression remained associated with RFS when corrected for age, sex and tumour site (P=0.006), but after adjusting additionally for SNB status did not reach statistical significance at the P=0.05 level (P=0.07). It did not remain significant in multivariable analysis with primary clinico-pathological characteristics (thickness, mitotic count, ulceration, vessel invasion) (Conway et al, 2009).
Increased osteopontin expression furthermore was associated with poorer OS (HR 1.6, 95% CI (1.1–2.5), P=0.02) in unadjusted analysis. The fold change between survivors and non-survivors was 1.3 (Conway et al, 2009). Osteopontin remained associated with OS after adjusting for age, sex and tumour site (P=0.02), but did not remain significant (P=0.07) after additionally adjusting for SNB status. It did not remain significant in multivariable analysis including primary clinico-pathological characteristics (thickness, mitotic count, ulceration, vessel invasion).
Figure 2 shows the ROC curves of different prognostic models for prediction of relapse (yes/no) for the total study group. A model using SNB status alone gave an AUC of 57.0% for relapse and 55.0% for OS (not shown). The clinico-pathological model (thickness, mitotic count, ulceration, vessel invasion, site, age and sex) gave a better AUC of 71.0% for relapse and 70.0% for OS. Combining this model with SNB status produced a small increase to 76.0% for relapse and 74.0% for OS.
Figure 3 shows the ROC curves of different prognostic models to predict relapse in the smaller tumour subset group. The AUC for osteopontin expression combined with the clinico-pathological features predicted relapse (67.4%) and survival (67.5%) better than SNB status alone (53.7, 50.6%) or the clinico-pathological features alone (66.1 and 67.0%). SNB status combined with the clinico-pathological features produced a small increase to 72.7% for relapse and 69.0% for survival prediction, which was not increased further with osteopontin expression.
Several clinico-pathological characteristics have been inconsistently associated with SNB positivity in a number of studies, including Clark's level, ulceration, mitotic count, microsatellites, vessel invasion, TILs, tumour site and age (Mraz-Gernhard et al, 1998; Porter et al, 2000; Wagner et al, 2000; McMasters et al, 2001; Nguyen et al, 2001; Rousseau et al, 2003; Sondak et al, 2004; Kesmodel et al, 2005; Wong et al, 2005; Kruper et al, 2006; Paek et al, 2007; Taylor et al, 2007; Pinero et al, 2008; Sartore et al, 2008). Although some previous studies have showed that patients in younger age groups were more likely to have a positive sentinel node (McMasters et al, 2001; Rousseau et al, 2003; Sondak et al, 2004; Paek et al, 2007), we found no association between age and SNB status in our study when analysing age as either a continous or categorical variable (<50 or >50 years). Variation in identified predictors from previous studies may be due to small studies and different study populations (Sondak et al, 2004; Wong et al, 2005). In comparison with previous studies, our study has a large sample size of SNB- positive patients and in addition has also looked at gene expression in the primary melanoma to investigate prognostic biomarkers.
In our study, the only clinico-pathological independent predictors of SNB positivity were mitotic count, tumour site and thickness. Although Breslow thickness is usually used alone to identify patients eligible for SNB, we have shown that we can predict positivity more effectively if we combine clinico-pathological characteristics in a model, and therefore considering these factors together would likely be more helpful in counselling patients about SNB. Osteopontin gene expression was the only gene on the DASL cancer panel to be significantly associated with SNB positivity. By adding osteopontin expression to the clinico-pathological model, the best AUC of 72.6% was achieved.
Osteopontin is a secreted phosphorylated glycoprotein also known as secreted phosphoprotein-1 or SPP1. It was originally identified as a bone matrix protein and subsequently identified as a cytokine (Wang and Denhardt, 2008) and has been implicated in the prognosis of different cancers, such as breast, lung, prostate, colon, as well as melanoma (Rittling and Chambers, 2004; Rangaswami et al, 2006). Several mechanisms by which SPP1 could be involved in cancer progression have been suggested. The interaction between osteopontin and its receptors, such as integrins, αvβ3 and CD44 (Wang and Denhardt, 2008), and epidermal growth factor receptor (Rangaswami et al, 2006) can lead to several signals including upregulation of metalloproteinase and stimulation of urokinase plasminogen activor. This forms a basis for metastatic potential by cell migration, cell adhesion and cell invasiveness (El-Tanani et al, 2006). Osteopontin is also an antiapoptotic factor and could promote cancer cell metastasis by preventing programmed cell death (Hsieh et al, 2006). In vitro studies have suggested a role for osteopontin in melanoma progression (Philip et al, 2001; Zhou et al, 2005). Very recently a large immunohistochemical study of 345 melanomas (256 with SNB status) also reported that increased osteopontin expression was an independent prognostic marker for melanoma being associated with SNB positivity, reduced RFS and OS (Rangel et al, 2008). The same authors have gone on to use osteopontin protein expression in a multimarker assay including two other markers not present on our DASL cancer panel (NCOA3, a member of the steroid receptor coactivator 1 family and RGS1, a GTPase-activating protein) and found the multimarker index to be the most significant factor in predicting RFS (Kashani-Sabet et al, 2009).
This study confirms that SNB is of strong prognostic value in melanoma patients with HRs for RFS and OS being similar to that seen in the third interim analysis of the multicentre-selective lymphadenectomy trial (Morton et al, 2006). SNB results are reported to provide a more accurate basis for formulating a prognosis than standard demographic and histopathological factors (Morton et al, 2006), and it is common in clinical practice to use SNB results alone to give prognostic information to melanoma patients. However, our study is the first to show that prognosis could be better predicted if clinicians used combined data from the pathology report of the primary tumour in a model rather than by using the SNB result. Combining SNB status with those clinico-pathological features, however, does produce a small further increase in prognostic predictive ability. These data therefore suggest that although SNB does improve prognostic estimates, the additional prognostic benefit from the operation is rather limited. Addition of osteopontin expression into a model did not further increase prognostic predictive ability once clinico-pathological features and SNB status had been considered in our data set.
Limitations of our multicentre study include involvement of many different pathologists, which can lead to variability in reporting. Cases were however generally reviewed by the melanoma multidisciplinary team pathology committee at each centre. The majority of cases furthermore (83%) originated from either St George's Hospital or The Royal Surrey hospital, where slides are reviewed by the same melanoma team involved in setting the EORTC guidance for pathological handling and assessment of sentinel nodes (Cook et al, 2003). However, as explained in the methodology some histological factors were assumed to be negative due to absence of reporting. Although a sensitivity analysis showed quantitavely similar results on the smaller completed data set, this is a limitation of the study. Patients were excluded from multivariable analysis due to incompleteness of pathological data. Owing to the retrospective nature of this study, the follow-up time was not standardised and varied considerably. Although the longest period of follow-up did reach 16.75 years, there were only three patients who had follow-up data over 10 years. We have used OS rather than melanoma-related survival in the analyses, as sufficient medical details, to be entirely sure of the cause of death, were not available in all non-survivors. However, 94% of deaths were known to be melanoma-related. With regard to gene-expression analysis, a main limitation of the study is the presence of a limited number of genes on the DASL Cancer Panel.
It was hoped that SNB would have therapeutic value for melanoma but there is no evidence currently that this is the case (Morton et al, 2006). The operation is well tolerated by the majority but is associated with morbidity (Nguyen et al, 2001), so that an estimate of the likelihood of positivity as reported here may help some patients to decide, whether to have the procedure or not. Our study adds further evidence that SNB positivity and outcome from melanoma is related to clinico-pathological features of the primary melanoma.
Although the results of SNB did add to prognostic estimates, our data suggest that it adds relatively little, if all the other clinico-pathological data are taken into account. The cost/benefit ratio from SNB therefore remains to be established. Although estimates of the predictive value of these models are given here, much larger pooled data analyses from many centres are necessary to develop robust predictive and prognostic models to allow use in clinical practice.
We thank J Lewis, P Brunyee, Dr M Marples, C Nolan Leeds; Dr M Green, Dr E Wong, L Baker, H Morgan, C Saunders, S Mackie, A Dodson, G Dodson, Royal Surrey County Hospital, Guildford; Dr E Thorne, Dr G Theaker, Sr M Faye, L Cousins, Sr J Gwilt, Southampton University Hospital; Dr A Maraveyas, Dr S Walton, Dr A Roy, C Farrah, J Butler, M Plumtree, Castle Hill Hospital, Hull; Prof A Dalgleish, Dr R Marsden, M Smith, J Hutchinson, C Knell, S De Coteau, St Georges Hospital, London. This work was supported by Cancer Research UK (Project Grants C8216/A6129 and C8216/A8168), and programme Grant C588/A4994. Angana Mitra was supported by a clinical fellowship awarded by the Special Trustees of the Leeds Teaching Hospitals Trust.
The authors declare no conflict of interest.
|Balch CM,Sober AJ,Soong SJ,Gershenwald JE. Year: 2003The new melanoma staging systemSemin Cutan Med Surg22425412773013|
|Balch CM,Soong SJ,Gershenwald JE,Thompson JF,Reintgen DS,Cascinelli N,Urist M,McMasters KM,Ross MI,Kirkwood JM,Atkins MB,Thompson JA,Coit DG,Byrd D,Desmond R,Zhang Y,Liu PY,Lyman GH,Morabito A. Year: 2001Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging systemJ Clin Oncol193622363411504744|
|Clark WH Jr,Elder DE,Guerry Dt,Braitman LE,Trock BJ,Schultz D,Synnestvedt M,Halpern AC. Year: 1989Model predicting survival in stage I melanoma based on tumor progressionJ Natl Cancer Inst81189319042593166|
|Cochran AJ,Elashoff D,Morton DL,Elashoff R. Year: 2000Individualized prognosis for melanoma patientsHum Pathol3132733110746675|
|Conway C,Mitra A,Jewell R,Randerson-Moor J,Lobo S,Nsengimana J,Edward S,Sanders DS,Cook M,Powell B,Boon A,Elliott F,de Kort F,Knowles MA,Bishop DT,Newton-Bishop J. Year: 2009Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survivalClin Cancer Res156939694619887478|
|Cook MG,Green MA,Anderson B,Eggermont AM,Ruiter DJ,Spatz A,Kissin MW,Powell BW. Year: 2003The development of optimal pathological assessment of sentinel lymph nodes for melanomaJ Pathol20031431912845627|
|El-Tanani MK,Campbell FC,Kurisetty V,Jin D,McCann M,Rudland PS. Year: 2006The regulation and role of osteopontin in malignant transformation and cancerCytokine Growth Factor Rev1746347417113338|
|Elder D,Murphy G. Year: 1991Malignant tumours (melanoma and related lesions)Vol. 2.Atlas of Tumor Pathology: Melanocytic Tumours of the Skin. Armed Forces Institute of Pathology: Washington|
|Ferrone CR,Panageas KS,Busam K,Brady MS,Coit DG. Year: 2002Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node statusAnn Surg Oncol963764512167577|
|Gershenwald JE,Thompson W,Mansfield PF,Lee JE,Colome MI,Tseng CH,Lee JJ,Balch CM,Reintgen DS,Ross MI. Year: 1999Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patientsJ Clin Oncol1797698310071292|
|Gutzmer R,Satzger I,Thoms KM,Volker B,Mitteldorf C,Kapp A,Bertsch HP,Kretschmer L. Year: 2008Sentinel lymph node status is the most important prognostic factor for thick (⩾4 mm) melanomasJ Dtsch Dermatol Ges619820318093216|
|Hsieh YH,Juliana MM,Hicks PH,Feng G,Elmets C,Liaw L,Chang PL. Year: 2006Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontinCancer Res667119712716849558|
|IlluminaYear: 2005aDASL Assay vs. Direct HybridizationTechnology SpotlightPub.No.470-2005-001|
|IlluminaYear: 2005bRNA Profiling with the DASL AssayTechnical BulletinPub.No. 470-2005-003|
|Jaeger J,Koczan D,Thiesen HJ,Ibrahim SM,Gross G,Spang R,Kunz M. Year: 2007Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissuesClin Cancer Res1380681517289871|
|Johnson OK Jr,Emrich LJ,Karakousis CP,Rao U,Greco WR. Year: 1985Comparison of prognostic factors for survival and recurrence in malignant melanoma of the skin, clinical Stage ICancer55110711173967194|
|Kashani-Sabet M,Venna S,Nosrati M,Rangel J,Sucker A,Egberts F,Baehner FL,Simko J,Leong SP,Haqq C,Hauschild A,Schadendorf D,Miller JR III,Sagebiel RW. Year: 2009A multimarker prognostic assay for primary cutaneous melanomaClin Cancer Res156987699219887476|
|Kauffmann A,Rosselli F,Lazar V,Winnepenninckx V,Mansuet-Lupo A,Dessen P,van den Oord JJ,Spatz A,Sarasin A. Year: 2008High expression of DNA repair pathways is associated with metastasis in melanoma patientsOncogene2756557317891185|
|Kesmodel SB,Karakousis GC,Botbyl JD,Canter RJ,Lewis RT,Wahl PM,Terhune KP,Alavi A,Elder DE,Ming ME,Guerry D,Gimotty PA,Fraker DL,Czerniecki BJ,Spitz FR. Year: 2005Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomasAnn Surg Oncol1244945815864482|
|Kruper LL,Spitz FR,Czerniecki BJ,Fraker DL,Blackwood-Chirchir A,Ming ME,Elder DE,Elenitsas R,Guerry D,Gimotty PA. Year: 2006Predicting sentinel node status in AJCC stage I/II primary cutaneous melanomaCancer1072436244517058288|
|Lens MB,Dawes M,Newton-Bishop JA,Goodacre T. Year: 2002Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsyBr J Surg891223122712296887|
|McMasters KM,Wong SL,Edwards MJ,Ross MI,Chao C,Noyes RD,Viar V,Cerrito PB,Reintgen DS. Year: 2001Factors that predict the presence of sentinel lymph node metastasis in patients with melanomaSurgery13015115611490343|
|Morton DL,Thompson JF,Cochran AJ,Mozzillo N,Elashoff R,Essner R,Nieweg OE,Roses DF,Hoekstra HJ,Karakousis CP,Reintgen DS,Coventry BJ,Glass EC,Wang HJ. Year: 2006Sentinel-node biopsy or nodal observation in melanomaN Engl J Med3551307131717005948|
|Mraz-Gernhard S,Sagebiel RW,Kashani-Sabet M,Miller JR III,Leong SP. Year: 1998Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanomaArch Dermatol1349839879722728|
|Nguyen CL,McClay EF,Cole DJ,O'Brien PH,Gillanders WE,Metcalf JS,Maize JC,Baron PL. Year: 2001Melanoma thickness and histology predict sentinel lymph node statusAm J Surg18181111248167|
|Paek SC,Griffith KA,Johnson TM,Sondak VK,Wong SL,Chang AE,Cimmino VM,Lowe L,Bradford CR,Rees RS,Sabel MS. Year: 2007The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanomaCancer10910010817146784|
|Philip S,Bulbule A,Kundu GC. Year: 2001Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cellsJ Biol Chem276449264493511564733|
|Pinero A,Canteras M,Ortiz E,Martinez-Barba E,Parrilla P. Year: 2008Validation of a nomogram to predict the presence of sentinel lymph node metastases in melanomaAnn Surg Oncol152874287718648880|
|Porter GA,Ross MI,Berman RS,Lee JE,Mansfield PF,Gershenwald JE. Year: 2000Significance of multiple nodal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsyAnn Surg Oncol725626110819364|
|Rangaswami H,Bulbule A,Kundu GC. Year: 2006Osteopontin: role in cell signaling and cancer progressionTrends Cell Biol16798716406521|
|Rangel J,Nosrati M,Torabian S,Shaikh L,Leong SP,Haqq C,Miller JR III,Sagebiel RW,Kashani-Sabet M. Year: 2008Osteopontin as a molecular prognostic marker for melanomaCancer11214415018023025|
|Rittling SR,Chambers AF. Year: 2004Role of osteopontin in tumour progressionBr J Cancer901877188115138464|
|Rousseau DL,Ross MI,Johnson MM,Prieto VG,Lee JE,Mansfield PF,Gershenwald JE. Year: 2003Revised american joint committee on cancer staging criteria accurately predict sentinel lymph node positivity in clinically node negative melanoma patientsAnn Surg Oncol1056957412794025|
|Sartore L,Papanikolaou GE,Biancari F,Mazzoleni F. Year: 2008Prognostic factors of cutaneous melanoma in relation to metastasis at the sentinel lymph node: a case-controlled studyInt J Surg620520918417434|
|Sondak VK,Taylor JM,Sabel MS,Wang Y,Lowe L,Grover AC,Chang AE,Yahanda AM,Moon J,Johnson TM. Year: 2004Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic modelAnn Surg Oncol1124725814993019|
|Taylor RC,Patel A,Panageas K,Busam K,Brady MS. Year: 2007Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanomaJ Clin Oncol78698752661733|
|Team RDC. Year: 2010R: A language and environment for statistical computingR Foundation for statistical computing|
|Wagner JD,Gordon MS,Chuang TY,Coleman JJ III,Hayes JT,Jung SH,Love C. Year: 2000Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanomaCancer8945346210918179|
|Wang KX,Denhardt DT. Year: 2008Osteopontin: role in immune regulation and stress responsesCytokine Growth Factor Rev1933334518952487|
|Winnepenninckx V,Lazar V,Michiels S,Dessen P,Stas M,Alonso SR,Avril MF,Ortiz Romero PL,Robert T,Balacescu O,Eggermont AM,Lenoir G,Sarasin A,Tursz T,van den Oord JJ,Spatz A. Year: 2006Gene expression profiling of primary cutaneous melanoma and clinical outcomeJ Natl Cancer Inst9847248216595783|
|Wong SL,Kattan MW,McMasters KM,Coit DG. Year: 2005A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging systemAnn Surg Oncol1228228815827679|
|Workman C,Jensen LJ,Jarmer H,Berka R,Gautier L,Nielser HB,Saxild HH,Nielsen C,Brunak S,Knudsen S. Year: 2002A new non-linear normalization method for reducing variability in DNA microarray experimentsGenome Biol3research004812225587|
|Zhou Y,Dai DL,Martinka M,Su M,Zhang Y,Campos EI,Dorocicz I,Tang L,Huntsman D,Nelson C,Ho V,Li G. Year: 2005Osteopontin expression correlates with melanoma invasionJ Invest Dermatol1241044105215854047|
Keywords: melanoma, prognosis, sentinel node biopsy, formalin-fixed tissue, osteopontin.
Previous Document: Role of human tissue kallikrein in gastrointestinal stromal tumour invasion.
Next Document: MicroRNA in lung cancer.